Enhanced liver injury and fibrosis markers after anti-PD-1 treatment in an HFD/CCl4-accelerated MASH-fibrosis mouse model
Immune checkpoint inhibitors show variable efficacy in hepatocellular carcinoma depending on etiology. In metabolic dysfunction-associated steatohepatitis (MASH), PD-1+ CD8+ T cells may paradoxically drive liver injury. We investigated whether PD-1 blockade exacerbates liver fibrosis in a non-neoplastic MASH environm...